{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:05:40Z","timestamp":1793444740370,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2024.e24715","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T05:05:50Z","timestamp":1705467950000},"page":"e24715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Qualification of a flow cytometry-based method for the evaluation of in vitro cytotoxicity of GTA002 natural killer cell therapy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2970-3220","authenticated-orcid":false,"given":"Monica","family":"Raimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra G.","family":"Zavoianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Meijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7528-2645","authenticated-orcid":false,"given":"Pascal","family":"Scholten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-6956","authenticated-orcid":false,"given":"Jan","family":"Spanholtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.heliyon.2024.e24715_bib1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.5966\/sctm.2014-0294","article-title":"Concise review: process development considerations for cell therapy","volume":"4","author":"Campbell","year":"2015","journal-title":"Stem. Cells. Transl. Med"},{"key":"10.1016\/j.heliyon.2024.e24715_bib2","first-page":"27","article-title":"Uncertainty and innovation: Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments","volume":"11","author":"Isasi","year":"2016","journal-title":"Appl. Transl. Geno"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24715_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jcyt.2020.06.005","article-title":"Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products","volume":"23","author":"Mfarrej","year":"2021","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24715_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jim.2010.09.036","article-title":"Recommendations for the validation of flow cytometric testing during drug development: II assays","volume":"363","author":"O'Hara","year":"2011","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24715_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cyto.b.21108","article-title":"Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria","volume":"84","author":"Wood","year":"2013","journal-title":"Cytometry. B. Clin. Cytom"},{"key":"10.1016\/j.heliyon.2024.e24715_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02169","article-title":"Flow cytometric analyses of lymphocyte markers in immune oncology: a comprehensive guidance for validation practice according to laws and standards","volume":"11","author":"Lambert","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24715_bib7","volume":"4","year":"2017","journal-title":"Manufacturing Practice Specific to Advanced Therapy Medicinal Products"},{"key":"10.1016\/j.heliyon.2024.e24715_bib8","series-title":"Validation of Analytical Procedures: Text and Methodology Step 5 NOTE for GUIDANCE on VALIDATION of ANALYTICAL PROCEDURES: TEXT and METHODOLOGY","year":"1995"},{"key":"10.1016\/j.heliyon.2024.e24715_bib9","first-page":"54","article-title":"Method validation by phase of development: an acceptable analytical practice","volume":"28","author":"Boudreau","year":"2004","journal-title":"Pharmaceut. Technol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24715_bib10","first-page":"32","article-title":"What is test method qualification? Proceedings of the WCBP CMC strategy forum, 24 July 2003","author":"Ritter","year":"2004","journal-title":"BioProcess. Int., 2"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24715_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcyt.2012.10.008","article-title":"Potency assay development for cellular therapy products: an ISCT\u2217 review of the requirements and experiences in the industry","volume":"15","author":"Bravery","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.heliyon.2024.e24715_bib12","series-title":"Potency Tests for Cellular and Gene Therapy Products","year":"2011"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24715_bib13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1039\/C5IB00007F","article-title":"Analysis of sphingosine kinase activity in single natural killer cells from peripheral blood","volume":"7","author":"Dickinson","year":"2015","journal-title":"Integr. Biol."},{"key":"10.1016\/j.heliyon.2024.e24715_bib14","series-title":"Guidance for Human Somatic Cell Therapy and Gene Therapy","year":"1998"},{"key":"10.1016\/j.heliyon.2024.e24715_bib15","series-title":"Guideline on Potency Testing of Cell Based Immunotherapy Medicinal Products for the Treatment of Cancer","year":"2016"},{"key":"10.1016\/j.heliyon.2024.e24715_bib16","series-title":"Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products - Draft Guidance for Industry","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e24715_bib17","series-title":"ISO 15189:2012 Medical Laboratories \u2014 Requirements for Quality and Competence","year":"2012"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024007461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024007461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:22:18Z","timestamp":1783930938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024007461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844024007461"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24715","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Qualification of a flow cytometry-based method for the evaluation of in vitro cytotoxicity of GTA002 natural killer cell therapy","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e24715"}}